COVID-19：Biofourmis､デジタル治療(DTx）Gaido Healthを買収：from Takeda Pharmaceuticals（動画）：
Biofourmis buys remote cancer monitoring startup Gaido Health：
Biofourmis收购远程癌症监测初创公司Gaido Health
Biofourmis：
ボストンのヘルスケア分析･デジタル治療（DTx）AIスタートアップが、動き出しました。
MedCity News：
BiofourmisがTakeda Pharmaceuticalsから、癌モニタリング/Gaido Healthを買収、
両社は、更なる提供製品/事業分野の拡大を目指します。
US Health Systems Are Applying Precision Medicine：
Biofourmis primarily focused on monitoring and treating patients with heart conditions via wearables
its AI-powered platform,
providing physicians a fuller picture into patients’ heart health and paving the way for more accurate, personalized care.
a recent Center for Connected Medicine survey：
But its move into oncology is a smart one, considering $151 billion is spent annually on cancer care in the US —
oncology tops the list of use cases for precision medicine among US health systems with initiatives underway, per a recent Center for Connected Medicine survey.
The Gaido Health purchase：
is the latest in a spate of activity signaling that Biofourmis is casting a wide net across the healthcare ecosystem —
which should benefit the startup both during the coronavirus pandemic and beyond.
Business Insider